Guillermo Arturo Morales

US Patent:

20140073584, Mar 13, 2014

Filed:

Sep 30, 2013

Appl. No.:

14/041279

Inventors:

Guillermo A. Morales - Oro Valley AZ, US
Kevin Weber - Carmel IN, US
Jessica Newblom - Indianapolis IN, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SIGNALRX PHARMACEUTICALS, INC. - San Diego CA

International Classification:

C07D 495/04
A61K 45/06
A61K 47/48
A61K 31/5377
A61K 31/538
C07F 5/02

US Classification:

514 193, 544146, 5142338, 544143, 544 73, 5142305, 544121, 544 69, 530330, 544141, 544131, 544 79, 5142325

Abstract:

The invention relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase.

US Patent:

20170334925, Nov 23, 2017

Filed:

Aug 9, 2017

Appl. No.:

15/672627

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SignalRx Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 495/04
A61K 31/541
A61K 31/538
A61K 45/06
A61K 31/5377

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.

US Patent:

20170101418, Apr 13, 2017

Filed:

Oct 19, 2016

Appl. No.:

15/297293

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SignalRx Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 495/04
A61K 31/541
A61K 31/538
A61K 31/5377
A61K 45/06

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.

US Patent:

20150344494, Dec 3, 2015

Filed:

May 4, 2015

Appl. No.:

14/702822

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SIGNALRX PHARMACEUTICALS, INC. - San Diego CA

International Classification:

C07D 495/04
A61K 31/5377
A61K 31/541
A61K 45/06

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.